Pipeline news

• Eyevance Pharmaceuticals Acquires Worldwide Rights to NEXAGON®

  03 October 2018

  

  Eyevance Pharmaceuticals, a Fort Worth-based pharmaceutical company committed to developing and commercializing innovative and impactful ophthalmic products, today announced a worldwide licensing agreement with OcuNexus Therapeutics for NEXAGON®, a 30-base antisense oligomer being developed for the orphan indication of persistent corneal epithelial defect (PED) nonresponsive to standard of care.

• Clearside Biomedical Appoints Jeffrey Edwards to Board of Directors

  26 September 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced that  Jeffrey Edwards  has been appointed to its Board of Directors, effective immediately.

• Marinus Completes Enrollment in its Magnolia Postpartum Depression Study

  25 September 2018

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced it has recently completed enrollment in its Magnolia Study – a Phase 2 clinical trial evaluating the safety, pharmacokinetics and efficacy of ganaxolone in women with postpartum depression.

• Syndax Announces Changes to its Board of Directors

  25 September 2018

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of  Jennifer Jarrett  and  William Meury to its Board of Directors, effective today.  Ms. Jarrett and Mr. Meury will succeed  Luke Evnin , Ph.D. and  Henry Chen , who resigned as active members of the Syndax Board of Directors, effective today.

• Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer

  24 September 2018

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated results from the ongoing ENCORE 601 cohort enrolling non-small cell lung cancer (NSCLC) patients previously treated with both chemotherapy and PD-(L)1 therapy. 

• Epic Sciences Announces Publication Showing Blood Test Could Help Select Metastatic Prostate Cancer Patients Who Respond to PSMA-Targeted Therapies

  24 September 2018

  

  Epic Sciences, in partnership with Memorial Sloan Kettering (MSK), have demonstrated that a liquid biopsy blood test may be used in clinical trials to find patients who are likely to benefit from PSMA-targeted therapies, before treatment is initiated. The blood test, developed by Epic Sciences, looks on the surface of circulating tumor cells (CTCs) for a specific protein, called prostate-specific membrane antigen (PSMA), that is highly expressed in prostate cancer. In the study, the presence of PSMA-positive CTCs in patients with metastatic prostate cancer was related to the patient’s therapeutic response and clinical outcomes to an antibody drug conjugate (ADC) therapy targeting PSMA-positive prostate cancer cells.

• Positive PEACHTREE Data to be Highlighted at EURETINA 2018

  18 September 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by  Ron Neumann , MD, Uveitis Specialist at  Maccabi Health Services ,  Tel Aviv, Israel  and co-Chair of the International Symposium of Ocular Pharmacology and Therapeutics, during a Uveitis Free Paper session at the upcoming  European Society of Retina Specialists (EURETINA) Congress  2018 in  Vienna, Austria.

• Data From Clearside Biomedical’s Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitis to be Presented at the Retina Society 51st Annual Scientific Meeting

  13 September 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by  Rahul N. Khurana , MD, an investigator for PEACHTREE, Partner at  Northern California Retina Vitreous Associates , and Clinical Associate Professor in Ophthalmology at  UCSF Medical Center , during a scientific session on Inflammation at the  Retina Society  51st Annual Scientific Meeting in  San Francisco , California. 

• Epic Sciences Announces Completion of $52 Million Series E Financing

  12 September 2018

  

  Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (NYSE: VAR). Existing investors, including Altos Capital Partners, Genomic Health, Inc., Domain Associates, VI Ventures, Alexandria Venture Investments, and Sabby Management, also participated in the financing.  

• Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery

  12 September 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Viral Kansara, Ph.D. to the position of Vice President, Discovery.